Abbott

By Laura Lovett 02:54 pm September 19, 2019
Sanofi has been active in the digital space this week inking two big deals: one with tech company Abbott and the other with digital platform Happify.  The first partnership with Abbott will combine the medtech company’s FreeStyle Libre, a continuous glucose monitoring system, and the pharma giant’s insulin dosing information to create smart pens and insulin titration apps.  Sanofi is currently...
By Dave Muoio 03:23 pm July 17, 2019
Following a major sales bump in the second quarter of 2019, Abbott Laboratories is planning to significantly ramp up manufacturing for its FreeStyle Libre continuous glucose monitoring system, the company shared during an investor’s call this morning. Specifically, the company highlighted a 72.9% increase in organic sales growth during the three-month period, reaching a worldwide total sales...
By Dave Muoio 04:03 pm June 10, 2019
On Friday, the American Diabetes Association kicked off its annual conference in San Francisco, where academics, vendors and other stakeholders congregated to unveil new study results and major announcements related to diabetes management. And while MobiHealthNews already put together a roundup featuring an opening salvo of the show’s announcements, the past few days have seen a tidal wave of new...
By Jonah Comstock 02:41 pm June 7, 2019
Implantable CGM company Senseonics has received approval from the FDA for the non-adjunctive indication for its Eversense device. Senseonics is only the third company to secure this indication, which allows a CGM to be used for insulin dosing in lieu of a fingerstick glucometer, though patients will still need to use fingersticks twice a day for calibration. The company plans to go live with the...
Novo Nordisk insulin pens
By Jonah Comstock 11:04 am February 20, 2019
Novo Nordisk’s connected insulin pens will integrate with the Abbott Freestyle Libre system, allowing Freestyle Libre users to see data about their insulin alongside their glucose readings, the companies announced this morning. "Lack of reliable information is a cause of huge frustration for many people with diabetes and their doctors," Anders Dyhr Toft, CVP of commercial innovation at Novo...
By Jonah Comstock 05:44 am November 7, 2018
By and large, Q3 2018 was a slow and steady quarter for pharma moves in digital health, at least in terms of publicly disclosed operations. At events during the quarter, the likes of Johnson & Johnson, AstraZeneca, Novartis and Sanofi discussed digital therapeutics and expressed a healthy mixture of skepticism and enthusiasm for the space. “These technologies have a tremendous opportunity to...
By Jonah Comstock 09:34 am November 1, 2018
Just a short while after securing a CE Mark for its second generation device, Abbott has been granted FDA clearance for FreeStyle LibreLink, a companion mobile app for its 10 to 14-day CGM. The launch adds a long-awaited feature for US users that’s been available for some time in Europe: users will be able to scan their sensors with an app on their smartphone — and see their latest reading —...

The Freestyle Libre 1.

By Jonah Comstock 05:49 pm October 1, 2018
Abbott has received CE Mark clearance for the second generation of its Freestyle Libre device, which will allow the company to make the device available to users in Europe. It will be rolled out gradually in Europe starting in the next few weeks, and it will be offered as the same price as the first generation device. Freestyle Libre 1, which has been available in Europe since 2014, is a fully...
By Jonah Comstock 08:00 am September 5, 2018
Correction: A previous version of this article failed to specify that the deal concerns Freestyle Libre Pro, rather than the consumer version, Freestyle Libre. Livongo Health, the digital chronic disease management company founded by former Allscripts CEO Glen Tullman, announced today that it will be the first United States enterprise diabetes management company to bring Abbott’s Freestyle Libre...
NHS drones
By Dave Muoio 01:29 pm July 30, 2018
Look to the skies. A recent report by Nesta, a global innovation foundation, conducted in collaboration with five UK cities suggests that no small number of regulatory and infrastructural obstacles stand in the way of medical drone deliveries in the country. While the technology could increase the testing speed and decrease costs for the UK’s National Health Service, the country would need to...